- Understand how leaders across sectors are harnessing the opportunity of addressing women’s health
- Learn where the opportunities are to reap the health and economic returns of closing the gap
- Get strategic insights on where the health of women market is heading – and how stakeholders can stay ahead
Innovation and Investment
Healthcare Costs and Outcomes
Lucy Perez
Senior Partner, Life Sciences
McKinsey & Company
Lucy is a Senior Partner in McKinsey’s Boston office. Lucy has 15+ years of experience advising CEOs and top teams at leading pharma, biotech and life sciences companies globally on growth strategy, innovation, sustainability, and organizational transformation.
Lucy co-leads McKinsey’s ESG domain and McKinsey’s All-In DEI efforts in North America. She also sponsors the Hispanic Latino Network at McKinsey and leads our research efforts on health equity.
Lucy works extensively with number of biopharma and life science clients on broad range of topics, with recent focus on ESG/ sustainability, evidence generation, and digital/analytics programs to improve patient outcomes and support sustainable, inclusive growth.
Led efforts for a leading biopharma to define their ESG strategy, partnership strategy, and stakeholder engagement approach
Led efforts for a leading biopharma to embed health equity as a core principle in their R&D priorities and ways of working across the value chain
Led efforts to assess internal and external portfolio productivity and pricing models to optimize the R&D strategy and redesign the organization for a top pharmaceutical company
Led efforts for a leading biopharma to transform how it engages with customers through digital transformation, applying advanced analytics and embedding agile ways of working across their six largest markets that delivered $300M+ of near-term growth
Sponsor of McKinsey’s Early Stage Investor Conference, an annual event convening 200+ entrepreneurs and 1000+ investors interested in bio/med/health tech and sustainability innovation
Before joining McKinsey, Lucy was a research fellow at Memorial Sloan-Kettering Cancer Center, where she was involved in the development of novel treatments for solid tumors. She was also a Howard Hughes Medical Institute research fellow at Harvard University while completing her doctoral studies. She is co-inventor on multiple patents and has published in peer-reviewed journals.
Lina Quinten
Director- European Patent Attorney
Fresenius Kabi Biosimilars
Leena Karttunen Contarinom
Senior Director IP
BioNTech
Heli Pihlajamaa
Principal Director
EPO
Niklas Wallsargård
CEO and Co-founder
Improvin’
Niklas Wallsargård is the CEO and Co-founder of Improvin’, a technology company tackling the critical global challenge: how to produce more food, more sustainably.
Improvin’ provides food and beverage brands, mills, and processors with the digital infrastructure to collect primary data, quantify sustainability insights, and drive positive impact within their supply chains, together with supplying partners and farmers.
Today, Improvin’ is recognized as one of Europe’s fastest-growing agri-food tech companies, trusted by industry leaders such as Mondelēz International, Barilla, AAK, and Oatly to achieve measurable and scalable sustainability impacts.
Drawing on over a decade of experience in the industry, Niklas is a strong advocate of leveraging smart technology to advance transparency and sustainability across the agri-food sector. His expertise lies in fostering cross-supply chain collaboration and empowering stakeholders to utilize technology for building a more resilient and biodiverse food system.
Claudette Fuller
Vice President, Non Clinical Safety & Toxicology
Genmab